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Abstract
Aims Cell therapy can be used to repair functionally impaired organs and tissues in humans. Although autologous cells have
an immunological advantage, it is difficult to obtain high cell numbers for therapy. Well-characterized banks of cells with hu-
man leukocyte antigens (HLA) that are representative of a given population are thus needed. The present study investigates
the HLA allele and haplotype frequencies in a cohort of heart failure (HF) patients.
Methods and results We carried out the HLA typing and the allele and haplotype frequency analysis in 247 ambulatory HF
patients. We determined HLA class I (A, B, and C) and class II (DRB1 and DQB1) using next-generation sequencing technology.
The allele frequencies were obtained using Python for Population Genomics (PyPop) software, and HLA haplotypes were es-
timated using HaploStats. A total of 30 HLA-A, 56 HLA-B, 23 HLA-C, 36 HLA-DRB1, and 15 HLA-DQB1 distinct alleles were iden-
tified within the studied cohort. The genotype frequencies of all five HLA loci were in Hardy–Weinberg equilibrium. We
detected differences in HLA allele frequencies among patients when the etiological cause of HF was considered. There were
a total of 494 five-loci haplotypes, five of which were present six or more times. Moreover, the most common estimated
HLA haplotype was HLA-A*01:01, HLA-B*08:01, HLA-C*07:01, HLA-DRB1*03:01, and HLA-DQB1*02:01 (6.07% haplotype fre-
quency per patient). Remarkably, the 11 most frequent haplotypes would cover 31.17% of the patients of the cohort in need
of allogeneic cell therapy.
Conclusions Our findings could be useful for improving allogeneic cell administration outcomes without concomitant
immunosuppression.
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Introduction
Heart failure (HF) is recognized as the true epidemic of the
21st century, affecting 1–2% of the adult population in devel-
oped countries, with a prevalence of ≥10% among those aged
70 years and older.1 Despite effective medication, left ven-
tricular assist devices, and surgeries that have improved
patient survival and comorbidities, replacement of the irrep-
arably injured heart by a donor organ is the only option in
some cases. However, this is often impaired by limited do-
nors, organ rejection, and receptors that need chronic immu-
nosuppression, which greatly reduces the patient’s quality of
life.2 In this context, cell-based therapy constitutes a promis-
ing option to restore damaged heart tissue.3,4 Autologous cell
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transplantation is preferred for regenerative purposes be-
cause there is no risk of immune rejection. However, the
use of autologous cells has some potential limitations. In gen-
eral, high cell numbers are not immediately available from
the same recipient. Moreover, cells isolated from elderly do-
nors show decreased differentiation and regenerative capa-
bilities, resulting in disappointing treatment outcomes. To
overcome these limitations, therapeutic strategies are using
allogeneic cells despite the need for human leukocyte antigen
(HLA) matching between the donor and recipient.
Histocompatibility is mainly determined by the major his-
tocompatibility complex genes (termed HLA in humans), the
most polymorphic genes in the human genome, which are lo-
cated on a 3.6 Mb region on chromosome 6p21. The HLA
genes have important roles in immune system regulation.5–7
Mainly, the HLA molecules present antigens to T lymphocytes
that direct the immune response and prevent autoreactivity.
It is important to note that the immune response against HLA
antigens is a major obstacle in organ and haematopoietic
stem cell transplantation. Currently, HLA typing is used to
search for an adult HLA match or cord blood donors to pre-
vent graft-versus-host disease and graft rejection during
transplantation.8–12 Thus, to increase the success of the func-
tional engraftment of a variety of cell suspensions or cell-
embedded implants, there is a need for ready-to-use banks
of HLA homozygous stem cells covering the largest number
of HLA combinations.
In this field of study, next-generation sequencing (NGS) ap-
proaches are based on amplification of the selected regions
by PCR followed by massively parallel sequencing of the
amplicons. In recent years, different HLA typing strategies
by NGS have been developed that provide high throughput
sequencing, unambiguous high-resolution results, and re-
duced costs per sample.13–16
Thus, the aim of this study was to perform a high-
resolution exploratory HLA analysis in a cohort of patients
with HF to determine the HLA-A, -B, -C, -DRB1, and -DQB1
allele and haplotype frequencies by NGS and develop conve-
niently designed donor panels. These data should maximize
the match probabilities for this patient population and
improve potential allogeneic cell therapy outcomes.
Methods
Study population
Our study cohort included 247 ambulatory patients who
attended a multidisciplinary HF unit (Table 1). The referral in-
clusion criteria are described elsewhere.17,18 All patients
attended follow-up visits at regular predefined intervals and
additional visits when required in cases of decompensation.
Each subject provided their written informed consent prior
to participation. The study protocol was approved by the Clin-
ical Research Ethics Committee of our institution (reference
number PI-17-044) and was designed in accordance with
the principles outlined in the 2013 revision of the Declaration
of Helsinki of 1975.19 Patients provide specific ancestry data.
Blood extraction and processing
Blood samples (~3 mL) were collected into EDTA tubes via
standard forearm venipuncture performed between 9:00 a.m.
Table 1 Baseline demographic, clinical, and biochemical data of
the study participants
n = 247
Age (years) 68.7 ± 12.2
Male sex 209 (84.6%)
Aetiology
Ischaemic heart disease 152 (61.5%)
Dilated CM 42 (17%)
Hypertensive CM 9 (3.6%)
Alcoholic CM 12 (4.9%)
Drug-induced CM 4 (1.6%)
Valvular disease 13 (5.3)
Hypertrophic CM 5 (2.0%)
Other 10 (4%)
HF duration (months) 60 (14–119)
LVEF 29.5% ± 6.5
NYHA functional class
I 8 (3.2%)
II 156 (63.2%)
III 81 (32.8%)
IV 2 (0.8%)
Co-morbidities
Hypertension 182 (73.7%)
Diabetes mellitus 112 (45.3%)
COPD 71 (28.7%)
Renal failurea 146 (59.1%)
Anaemiab 116 (47%)
Atrial fibrillation/flutter 100 (40.5%)
Biochemical
Na 139 ± 3.9
Haemoglobin 12.9 ± 1.6
eGFR 55.5 ± 25.2
NTproBNP 1673 (702–4115)
Treatments
ACEI/ARB 207 (83.8%)
Beta-blockers 234 (94.7%)
MRA 171 (69.2%)
Loop diuretics 214 (86.6%)
Digoxin 70 (28.3%)
Ivabradine 38 (15.4%)
Statins 199 (80.6%)
ICD 83 (33.6%)
CRT 51 (20.6%)
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin
receptor blocker; CM, cardiomyopathy; CRT, cardiac
resynchronization therapy; ICD, implantable cardioverter device;
LVEF, left ventricular ejection fraction; MRA: mineral corticoid re-
ceptor antagonist; NYHA, New York Heart Association.
Data expressed as mean ± standard deviation, median (25th–75th
percentiles), or absolute number (percentage).
aeGFR (CKD-EPI) <60 mL/min/1.73 m2.
bHb < 12 g/dL in women and <13 g/dL in men.
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and 11:00 a.m. and were processed within 4 h after collec-
tion. Samples and data from patients included in this study
were processed and collected by the IGTP-HUGTP Biobank
from the Spanish National Biobanks Network of Instituto de
Salud Carlos III (PT13/0010/0009) and Tumour Bank Network
of Catalonia. All laboratory measurements were performed
by staff blinded to the patients’ clinical characteristics. DNA
was extracted from peripheral blood using the QIAsymphony
DNA purification system (Qiagen, Toronto, Canada) according
to the manufacturer’s protocol.
Table 2 Class I allele frequencies in heart failure patients
HLA-A N AF HLA-B N AF HLA-C N AF
A*02:01 119 24.09 B*44:03 46 9.31 C*07:01 66 13.36
A*01:01 66 13.36 B*18:01 37 7.49 C*04:01 64 12.96
A*24:02 50 10.12 B*44:02 36 7.29 C*05:01 58 11.74
A*03:01 46 9.31 B*08:01 31 6.28 C*06:02 47 9.51
A*29:02 35 7.09 B*51:01 31 6.28 C*16:01 38 7.69
A*11:01 31 6.28 B*07:02 27 5.47 C*07:02 33 6.68
A*26:01 19 3.85 B*14:02 21 4.25 C*12:03 32 6.48
A*30:02 15 3.04 B*38:01 18 3.64 C*08:02 24 4.86
A*32:01 14 2.83 B*35:01 18 3.64 C*01:02 22 4.45
A*31:01 12 2.43 B*50:01 17 3.44 C*02:02 21 4.25
A*23:01 10 2.02 B*15:01 16 3.24 C*03:03 17 3.44
A*68:01 9 1.82 B*57:01 14 2.83 C*15:02 14 2.83
A*33:01 8 1.62 B*49:01 14 2.83 C*03:04 14 2.83
A*68:02 8 1.62 B*45:01 13 2.63 C*12:02 9 1.82
A*25:01 8 1.62 B*27:05 12 2.43 C*14:02 7 1.42
A*30:01 8 1.62 B*40:01 11 2.23 C*17:01 7 1.42
A*02:05 7 1.42 B*52:01 10 2.02 C*15:05 6 1.21
A*33:03 5 1.01 B*35:03 10 2.02 C*03:02 3 0.61
A*66:01 5 1.01 B*53:01 9 1.82 C*05:09 3 0.61
A*03:02 4 0.81 B*40:02 7 1.42 C*02:10 3 0.61
A*02:02 3 0.61 B*37:01 7 1.42 C*07:04 3 0.61
A*69:01 3 0.61 B*39:01 7 1.42 C*16:02 2 0.40
A*24:03 2 0.40 B*07:05 6 1.21 C*15:06 1 0.20
A*74:03 1 0.20 B*35:02 6 1.21
A*02:03 1 0.20 B*58:01 6 1.21
A*26:08 1 0.20 B*13:02 6 1.21
A*30:04 1 0.20 B*56:01 5 1.01
A*01:02 1 0.20 B*41:01 4 0.81
A*29:01 1 0.20 B*35:08 4 0.81
A*24:10 1 0.20 B*39:06 4 0.81
B*41:02 4 0.81
B*15:03 3 0.61
B*15:17 3 0.61
B*14:01 3 0.61
B*55:01 3 0.61
B*44:05 3 0.61
B*40:06 2 0.40
B*50:02 2 0.40
494 100.00 494 100.00
B*51:08 1 0.20
B*39:24 1 0.20
B*15:09 1 0.20
B*27:03 1 0.20
B*18:03 1 0.20
B*57:03 1 0.20
B*51:02 1 0.20
B*78:01 1 0.20
B*35:30 1 0.20
B*47:01 1 0.20
B*27:12 1 0.20
B*15:24 1 0.20
B*27:02 1 0.20
B*44:130 1 0.20
B*15:16 1 0.20
B*15:18 1 0.20
B*46:01 1 0.20
B*39:02 1 0.20
494 100.00
AF, allelic frequency; N, number of observed alleles.
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Human leukocyte antigen typing
HLA-A, -B, -C, -DRB1, and -DQB1 were analysed by NGS using
the Illumina MiSeq instrument. Focusing on key exons, the
analysis characterized HLA exons 2 to 4 for class I alleles
and exons 2 and 3 for class II alleles using the NGSengine soft-
ware (version 2.8.0, GenDX, Netherlands) and the November
2017 IPD-IMGT/HLA database 3.30.0, as the allele reference
library. The HLA allele frequencies were estimated using
PyPop software (version http://www.pypop.org).
Human leukocyte antigen haplotype determination
We determined the HLA haplotype by complete typing of
HLA-A, -B, -C, -DRB1, and -DQB1. The haplotypes were not
determined by segregation because no parents’ samples
were available. The HLA haplotype estimation was performed
using HaploStats (http://www.haplostats.org) software based
on haplotype frequencies. The haplotypes were counted
using Microsoft Excel. The exact test for deviation from
Hardy–Weinberg Equilibrium was evaluated by PyPop
software, which uses an algorithm to estimate the P-value.
Also, PyPop analyses were performed to estimate the
haplotype, linkage disequilibrium (D), and relative linkage
disequilibrium (D’).
Results
Table 1 shows the clinical characteristics of the studied popu-
lation. In general, patients were middle-aged and predomi-
nantly male, frequently had an ischaemic aetiology, were in
NYHA functional class II or III, and were treated following con-
temporary guidelines. Within the cohort of HF patients, we
measured the HLA-A, -B, -C, -DRB1, and -DQB1 allele and hap-
lotype frequencies using whole genomic DNA extracted from
peripheral blood samples and high-resolution NGS technol-
ogy. While HLA class I alleles were defined based on the
sequences of exons 2, 3, and 4, HLA class II alleles were
designated based on the sequences of exons 2 and 3. Once
HLA typing was performed, we noticed that all patients were
heterozygous at the five HLA loci. Furthermore, the genotype
frequencies of all five HLA loci were in Hardy–Weinberg
equilibrium proportions.
In this patient cohort, the number of distinct HLA alleles
were 30 for HLA-A, 56 for HLA-B, 23 for HLA-C, 36 for HLA-
DRB1, and 15 for HLA-DQB1. Three HLA-A alleles, A*02:01
(24.09%), A*01:01 (13.36%), and A*24:02 (10.12%), were
the most frequent HLA-A alleles. Eleven of the HLA-A alleles
identified (36.66%) appeared less than 1%. With regard to
HLA-B, B*44:03 (9.31%), B*18:01 (7.49%), B*44:02 (7.29%),
B*08:01 (6.28%), B*51:01 (6.28%), and B*07:02 (5.47%)
exhibited the highest frequencies. Twenty-nine of the HLA-B
alleles (32%) appeared less than 1%. As for HLA-C, three al-
leles, C*07:01 (13.36%), C*04:01 (12.96%), and C*05:01
(11.74%), exhibited the most frequencies. Almost one-
quarter of the HLA-C alleles appeared with a frequency less
than 1% (Table 2).
The most likely HLA-DRB1 alleles were DRB1*07:01
(14.78%) and DRB1*03:01 (13.16%). Eleven HLA-DRB1 alleles
(22.22%) were observed less than 1%. The most frequent
alleles were DQB1*03:01 (15.38%), DQB1*05:01 (14.57%),
DQB1*02:01 (13.36%), and DQB1*02:02 (13.36%). All
HLA-DQB1 alleles appeared six or more times (Table 3).
Importantly, the most frequent HLA alleles in this HF pop-
ulation are in line with the most frequent HLA alleles pre-
sented in our reference population. In particular, we used
as reference database all NGS-typed samples collected in
the bank of samples of Blood and Tissue Bank (Barcelona,
Spain). Because Blood and Tissue Bank implemented NGS
for typing their samples in 2015, they have assessed more
than 15 000 samples from our area (data not shown). Also,
Table 3 Class II allele frequencies in heart failure patients
HLA-DRB1 N AF HLA-DQB1 N AF
DRB1*07:01 73 14.78 DQB1*03:01 76 15.38
DRB1*03:01 65 13.16 DQB1*05:01 72 14.57
DRB1*15:01 40 8.10 DQB1*02:01 66 13.36
DRB1*13:01 36 7.29 DQB1*02:02 66 13.36
DRB1*01:01 35 7.09 DQB1*03:02 48 9.72
DRB1*11:01 27 5.47 DQB1*06:02 38 7.69
DRB1*11:04 23 4.66 DQB1*06:03 36 7.29
DRB1*01:02 21 4.25 DQB1*03:03 22 4.45
DRB1*04:04 17 3.44 DQB1*04:02 15 3.04
DRB1*13:02 17 3.44 DQB1*05:03 13 2.63
DRB1*04:05 13 2.63 DQB1*05:02 12 2.43
DRB1*09:01 11 2.23 DQB1*06:04 9 1.82
DRB1*11:02 10 2.02 DQB1*06:09 8 1.62
DRB1*04:02 10 2.02 DQB1*06:01 7 1.42
DRB1*16:01 10 2.02 DQB1*03:19 6 1.21
DRB1*08:01 10 2.02
DRB1*04:03 9 1.82
DRB1*10:01 9 1.82
DRB1*15:02 8 1.62
DRB1*14:54 7 1.42
DRB1*04:01 6 1.21
DRB1*13:03 6 1.21
DRB1*04:07 5 1.01
DRB1*01:03 5 1.01
DRB1*12:01 5 1.01
DRB1*14:04 4 0.81
DRB1*04:06 2 0.40
DRB1*13:05 2 0.40
DRB1*16:02 1 0.20
DRB1*15:03 1 0.20
DRB1*04:11 1 0.20
DRB1*14:05 1 0.20
DRB1*13:11 1 0.20
DRB1*08:04 1 0.20
DRB1*04:37 1 0.20
DRB1*12:02 1 0.20
494 100.00 494 100.00
AF, allele frequency; N, number of observed alleles.
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we used the Allele Frequency Net Database as a reference
(http://allelefrequencies.net).
We likewise studied the HLA allele, taking into account
the two main etiological causes of HF in our cohort of
patients. Of note, the cohorts of patients with dilated cardio-
myopathy (DCM) and ischaemic HF (IHF) showed some
differences on HLA allele frequencies. Regarding DCM
patients, HLA-A*03:01 (5.95%), HLA-B*08:01 (1.19%), and
HLA-DRB1*03:01 (8.33%) were less represented as
compared with the IHF group and reference database. On
the contrary, HLA-C*04:01 (20.24%), HLA-DRB1*04:03
(3.57%), HLA-DRB1*04:04 (4.76%), and HLA-DRB1*04:05
(3.57%) were more common on patients with DCM. On the
other hand, the IHF patients had over represented
HLA-DQB1*05:01 (16.45%) and HLA-C*05:01 (12.50%).
HLA-DQB1*03:01 (12.50%) was also less expressed in this
cohort of patients.
When ethnicity of our cohort of HF patients was consid-
ered, we identified 383 unique haplotypes from the 494
five-loci haplotypes analysed, five of which were present six
or more times (Table S1). The most common five-loci haplo-
type detected was A*01:01-B*08:01-C*07:01-DRB1*03:01-
DQB1*02:01 (3.04%), which had a haplotype frequency of
6.07% per patient (Table 4 ). Remarkably, 31.17% of patients
would be covered by the 11 most frequent HLA haplotypes
(Figure 1).
Lastly, we focused on the two main etiological causes
(DCM and IHF) (Tables S2–S7 ). In this context, we found
that the frequent haplotype A*29:02-B*44:03-C*16:01-
DRB1*07:01-DQB1*02:02 was not present in any of the
DCM patients. Moreover, the haplotype A*01:01-B*08:01-
C*07:01-DQB1*02:01-DRB1*03:01 (1.19%) was found
only once.
Discussion
The increased incidence and prevalence of congestive HF
have led to the need for novel treatment strategies, including
cell-based therapies. Translating cell administration into the
clinic requires the ability to deliver a safe and efficacious
product that is ready-to-use at the optimal dosage. Allogeneic
cell therapy is immediately available and provides a high
number of cells20; however, it is clearly a disruptive concept
in biology. The standard immunologic dogma holds that any
foreign tissue will elicit an immune reaction.20 This is clearly
apparent in whole organ, tissue, or cell transplants in which
aggressive immunosuppression is necessary to protect
allografts from rejection.21 Thus, the analysis of histocompat-
ibility is most relevant in this field, where differences be-
tween the donor’s HLA alleles and the recipient’s trigger the
immune system to reject the transplant. The World Marrow
Donor Association guidelines for establishing the extent and
quality of histocompatibility testing for unrelated donor regis-
tries, umbilical cord blood banks, and transplant centres
involved an international exchange of cells for allogeneic
therapy.22
Table 4 The most frequent haplotypes in heart failure patients
ID Haplotypes N HF PHF
1 A*01:01, B*08:01, C*07:01, DRB1*03:01, DQB1*02:01 15 3.04 6.07
2 A*29:02, B*44:03, C*16:01, DRB1*07:01, DQB1*02:02 11 2.23 4.45
3 A*30:02, B*18:01, C*05:01, DRB1*03:01, DQB1*02:01 10 2.02 4.05
4 A*23:01, B*44:03, C*04:01, DRB1*07:01, DQB1*02:02 7 1.42 2.83
5 A*02:01, B*08:01, C*07:01, DRB1*03:01, DQB1*02:01 6 1.21 2.43
6 A*33:01, B*14:02, C*08:02, DRB1*01:02, DQB1*05:01 6 1.21 2.43
7 A*02:01, B*18:01, C*05:01, DRB1*03:01, DQB1*02:01 5 1.01 2.02
8 A*02:01, B*44:02, C*05:01, DRB1*01:01, DQB1*05:01 5 1.01 2.02
9 A*02:01, B*07:02, C*07:02, DRB1*15:01, DQB1*06:02 4 0.81 1.62
10 A*24:02, B*45:01, C*16:01, DRB1*10:01, DQB1*05:01 4 0.81 1.62
11 A*02:01, B*44:02, C*05:01, DRB1*11:01, DQB1*03:01 4 0.81 1.62
31.17
HF, haplotype frequency; ID, identification; N, number of observed haplotypes; PHF, population haplotype frequency.
Figure 1 The 11 most frequent haplotypes are present in the 31.17% of
the patients of our cohort. Each column represents the accumulated per-
centage of individuals that have each haplotype (referenced in Table 4 as
ID) and its previous ones.
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As the field of cell-based therapy evolves, it has become
evident that various cell types – mesenchymal stem cells
(MSCs) being the prototype – have sufficient ability to evade
and/or suppress the immune system to the extent that they
may be used as allografts without requiring concomitant im-
munosuppression.23,24 Moreover, increasing evidence has
suggested that the effect of infused MSCs is not direct, but
rather due to paracrine signalling. Paracrine signalling is con-
sistent with findings in which a low number of retained or
seeded cells could promote restorative effects, such as
forming vessels to protect resident cardiomyocytes from ap-
optosis, and mobilize host stem or progenitor cells to poten-
tiate both vascularization and cardiomyogenesis.25,26 Thus,
alternative cell sources are being examined, including plurip-
otent stem cells (iPS). The iPS cells are in the preclinical stage,
can be generated after inducing the expression of transcrip-
tion factors associated with pluripotency, and exhibit unlim-
ited self-renewal and differentiation to many cell lineage
types.27,28 Clinically, the pluripotency state of iPS allows for
a wide range of disease treatments, and their pre-
differentiation ex vivo may guarantee their safeness.29–31
Nevertheless, their high proliferation rate increases the risks
associated with products containing iPS (e.g. risk of tumour
formation).32 Indeed, in contrast to MSCs, derivatives from
iPS can currently only be used for autologous cell administra-
tion. Thus, it is necessary to generate iPS banks for HLA-
matched allogeneic cell therapy based on known donor and
recipient HLA types. Moreover, the major purposes of devel-
oping these iPS banks are to ensure cost-effectiveness, solve
the issue of high time consumption in processing autologous
iPS or derivatives, and guarantee their utility for acute
patients.33
The presented results showed that the most common five-
loci haplotype detected was A*01:01-B*08:01-C*07:01-
DRB1*03:01-DQB1*02:01 (3.04%), which had a haplotype
frequency of 6.07% per patient in our cohort. This
HLA-estimated haplotype within our cohort of patients is
common and conserved in North European Caucasians.34–36
In particular, when we consider the Allele Frequency Net
Database, the haplotype frequency of A*01:01-B*08:01-
C*07:01-DQB1*02:01-DRB1*03:01 in North European
Caucasians is over 3%. Remarkably, 31.17% of patients in
our cohort would be covered by the 11 most frequent haplo-
types. This finding from a real setting is in agreement with
that previously reported by Gourraud et al.37 These authors
developed a mathematical model and calculated that, in
order to obtain iPS for the 20 most frequent HLA haplotypes,
26 000 European-American donors would need to be
analysed and 50% would be compatible. This confirms that
relatively few, but very well selected, donors would give rise
to iPS lines with a very important clinical utility. To carry out
the screening and identify the largest number of possible
donors, it would be necessary to collaborate with multiple
centres worldwide.38 This study searched among potential
bone marrow donors and samples preserved in umbilical cord
banks, because both are already HLA typed. The findings from
this study will be part of a subsequent study of samples
stored in the Catalan Blood and Tissue Bank (BST). The search
and selection of HLA homozygous cord units for the 11 most
frequent haplotypes could extend future administrations of
therapeutic cells.
Remarkably, despite further studies using a large cohort of
HF patients are warranted to potentially assess statistical sig-
nificances, our findings suggest a protective role for some
haplotypes such as HLA-B*08:01 and HLA-DQB1*03:01,
which are underrepresented in DCM and IHF patients,
respectively. In contrast, the haplotypes HLA-DRB1*04:03,
HLA-DRB1*04:04, and HLA-DRB1*04:05 could be associated
with DCM because their frequencies are higher compared
with IHF patients and control subjects (reference database).
In sum, the present study revealed, for the first time, the
most frequent HLA allele combinations within a cohort of
ambulatory HF patients. Autologous administration of MSC
and iPS is still preferred for regenerative purposes because
the rejection risks are avoided. However, our findings
suggest that safe iPS-based products, e.g. predifferentiated
cardiomyocytes or endothelial cells, can be useful for treating
these patients in future clinical trials if the recipient and
donor are HLA matched. Indeed, an iPS bank of 11 cell lines
will cover almost one-third of this patient population.
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